About the Study of AMP-270
Trial Name: Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma
ClinicalTrials.gov Indentifier: NCT05494697
Completion Date: January 2027
Recruitment Status: Not yet recruiting
Sponsor: AIM ImmunoTech Inc.